News Releases

Ludwig MIT study identifies new targets for cancer vaccines

September 16, 2021, NEW YORK – Researchers led by Ludwig MIT Co-director Tyler Jacks have found that vaccinating against certain cancer antigens—telltale fragments of aberrant proteins that reveal cancer cells to the immune system—can reawaken dormant anti-tumor T cell populations, strengthen the overall immune response and shrink tumors in mice.

When cells turn cancerous, they produce randomly mutated proteins that can serve as individualized cancer antigens. T cells that recognize these “neoantigens” start destroying the cancerous cells that display them. But those T cells eventually experience a phenomenon known as “exhaustion,” in which they enter a lethargic and dysfunctional state. Additionally, previous studies have shown that of the hundreds of neoantigens found in most tumors, only a small subset generate a T cell response.

The study, reported September 16th in Cell, helps shed light on why that is. In experiments on mice with lung tumors, the researchers found that as tumor-targeting T cells arise, subsets that target different neoantigens compete with each other, eventually leading to the emergence of a dominant population of T cells. After these T cells become exhausted, they remain in the tumor microenvironment and suppress competing T cell populations that target different neoantigens.

Jacks—who is also the David H. Koch Professor of Biology at MIT and a member of the Koch Institute for Integrative Cancer Research—and his colleagues found that vaccinating mice with neoantigens targeted by the suppressed T cells rejuvenated those T cell populations and increased the breadth and functionality of the T cell response. When they used one of those neoantigens in combination with a dominant neoantigen to vaccinate mice with lung tumors, tumors shrank by an average of 27 percent. Neoantigens associated with the suppressed T cell responses tended to weakly bind the immune cells responsible for presenting the antigen to T cells. Jacks and colleagues suggest that inclusion of weak binders in neoantigen vaccines for humans may provide greater therapeutic benefit than previously appreciated.

After vaccination, the T cell population included a subset that has the potential to continuously refuel the response, which could allow for long-term control of tumors. These T cells also caried a marker of response to checkpoint blockade immunotherapy, suggesting a combination therapy for evaluation in future studies.

The release from which this summary is derived can be found here.


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?